Bosulif: protein kinase inhibitor for chronic myeloid leukaemia

Bosulif (bosutinib) is indicated in chronic, accelerated or blast phase Philadelphia chromosome positive chronic myeloid leukaemia (CML) previously treated with one or more tyrosine kinase inhibitors and where imatinib, nilotinib and dasatinib are not appropriate.

Bosulif (bosutinib) is licensed for chronic myeloid leukaemia (blood cells from bone marrow in a case of CML, pictured) | SCIENCE PHOTO LIBRARY
Bosulif (bosutinib) is licensed for chronic myeloid leukaemia (blood cells from bone marrow in a case of CML, pictured) | SCIENCE PHOTO LIBRARY

PHARMACOLOGY

Bosutinib is a protein kinase inhibitor which inhibits the abnormal Bcr-Abl kinase that promotes CML.1

CLINICAL STUDIES

Bosutinib was evaluated in a phase I/II open-label study involving 570 patients with chronic, accelerated or blast phase, imatinib-resistant or imatinib-intolerant CML that had been previously treated with at least one tyrosine kinase inhibitor.1

Marketing approval was granted primarily on the basis of findings in 52 patients deemed as having an unmet medical need because other tyrosine kinase inhibitors were not appropriate due to resistance or the risk of adverse effects. Of these, 36 had chronic phase CML and 16 had either accelerated or blast phase CML.1

In patients with chronic phase CML treated previously with imatinib only, 59% (95% CI 52.9-65.0) achieved a major cytogenetic response (MCyR) at week 24 (primary efficacy endpoint). This compared with 40.9% (95% CI 31.6-50.7) of those treated previously with imatinib and dasatinib or nilotinib.1

In patients with accelerated or blast phase CML treated previously with at least imatinib, the proportions achieving MCyR at week 24 were 34.8% (95% CI 23.7-47.2) and 29.6% (95% CI 18.0-43.6), respectively.1

The most commonly reported adverse effects were GI upset, thrombocytopenia, rash, anaemia, pyrexia and raised serum ALT. 1

Bosulif has been given conditional marketing approval pending further evidence of clinical benefit and safety.

References:

  1. Bosulif Summary of Product Characteristics, March 2013

View Bosulif drug record

Further information: Pfizer

Follow MIMS on Twitter


Read these next

Iclusig: new protein kinase inhibitor for leukaemia

Iclusig: new protein kinase inhibitor for leukaemia

Iclusig (ponatinib) is a protein kinase inhibitor that...


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.